UTHRUnited Therapeutics Corp

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Martine A. Rothblatt

Location

Maryland, USA

Exchange

Nasdaq

Website

https://unither.com

Summary

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Company Info

CEO

Martine A. Rothblatt

Location

Maryland, USA

Exchange

Nasdaq

Website

https://unither.com

Summary

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

AI Insights for UTHR
5 min read

Quick Summary

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on chronic and life-threatening diseases, with its strongest commercial position in pulmonary arterial hypertension and related pulmonary vascular disorders. The company sells therapies based largely on treprostinil, including inhaled, infused, and dry-powder formulations that are intended to improve exercise capacity and symptoms in patients with PAH and PH-ILD. Its main customers include specialty pharmacies, hospitals, prescribing pulmonologists, cardiologists, transplant specialists, and patients with rare cardiopulmonary diseases who require long-term therapy. United Therapeutics also invests in longer-term organ-manufacturing and xenotransplantation programs, which could eventually address shortages of transplantable organs. The company is headquartered in Silver Spring, Maryland, and is led by CEO Martine A. Rothblatt. Its revenue base is concentrated in high-value specialty medicines, which makes product durability, patent protection, clinical evidence, and reimbursement access especially important to the business.

Strengths

•

United Therapeutics’ primary strength is its focused leadership position in pulmonary arterial hypertension and related rare cardiopulmonary diseases.

•

The company has a well-established treprostinil franchise with multiple delivery formats, which helps it serve different patient needs and defend its market position.

•

Its financial profile appears strong, with high gross profit, meaningful operating income, and a market capitalization of about $24.2 billion in the provided data.

•

The company also has a relatively low beta of 0.49, suggesting its shares may be less volatile than the broader market, although company-specific clinical and regulatory events can still be significant.

•

Management has shown a willingness to invest beyond current products into ambitious areas such as organ manufacturing and xenotransplantation.

Key Risks

•

United Therapeutics faces competitive risk from established and emerging therapies in PAH, PH-ILD, and adjacent lung diseases.

•

Merck’s Winrevair, Johnson & Johnson’s pulmonary hypertension portfolio, Liquidia’s potential inhaled treprostinil competition, and new pulmonary fibrosis therapies could all affect growth expectations.

•

Regulatory risk is significant because products such as Tresmi, TETON-related therapies, and xenotransplantation programs require successful trials, filings, inspections, and approvals.

•

Commercial risk is also meaningful because cough, device usability, adherence, reimbursement, and physician preferences can all influence inhaled therapy adoption.

What to Watch

In the most recent reported data, United Therapeutics generated operating revenue of $783.3 million and total revenue of $783.3 million, indicating continued scale in its specialty pharmaceutical business.
The company produced total gross profit of $683.8 million, operating income of $330.8 million, and net income of $333 million, showing strong profitability for the quarter.
The company’s basic EPS was listed at $7.82 and diluted EPS at $7.27, which supports the view that earnings remain a key element of the investment story.
Recent news also emphasized strong Tyvaso performance, record annual revenue above $3 billion, and continued momentum in inhaled treprostinil products.
Management highlighted plans for Tresmi, a soft-mist treprostinil inhaler designed to reduce cough, and continued progress in pipeline assets such as TETON and Rolinapag.
The quarter also sits against a backdrop of investor attention to competition, launch execution, seasonality, and the timing of important clinical readouts.

Price Drivers

•

United Therapeutics’ stock price is driven primarily by revenue growth from Tyvaso, Tyvaso DPI, Remodulin, and other treprostinil-based therapies.

•

The company reported strong profitability metrics, including quarterly operating revenue of $783.3 million, total gross profit of $683.8 million, operating income of $330.8 million, and net income of $333 million in the provided data.

•

Valuation also matters, with a price-to-earnings ratio of about 18.4, an earnings yield of about 5.4%, and an enterprise-value-to-EBITDA ratio of about 13.5.

•

Investors are likely watching whether the company can sustain growth toward management’s stated ambition of a $4 billion revenue run rate by the end of 2027.

•

Major clinical and regulatory catalysts, including Tresmi, TETON-1, Rolinapag, and xenotransplantation progress, can also move the stock sharply.

•

Competitive developments from Merck, Liquidia, Johnson & Johnson, and other pulmonary disease companies may affect expectations for future market share and pricing.

Recent News

•

Recent news indicates that United Therapeutics plans to file Tresmi, a soft-mist treprostinil inhaler, with a potential launch following regulatory progress.

•

Management has cited early data suggesting up to 90% less coughing, which could be important for inhaled treprostinil adherence and patient comfort.

•

The company also reported record 2025 revenue above $3 billion, with Q4 revenue of about $790 million and Tyvaso revenue of about $464 million.

•

United Therapeutics has discussed key upcoming catalysts including super-prostacyclin programs, TETON-1 idiopathic pulmonary fibrosis readouts, Rolinapag, and AI lung-model partnerships.

•

The company previously agreed to acquire Miromatrix Medical to expand organ-manufacturing programs involving bioengineered kidneys and livers.

•

News coverage has also highlighted CEO Martine Rothblatt’s compensation, leadership profile, and public comments on gender equity and employee stock ownership.

Market Trends

•

The pulmonary hypertension market is becoming more competitive as large pharmaceutical companies and smaller biotechnology firms develop new mechanisms, improved delivery systems, and disease-modifying approaches.

•

Inhaled therapies are evolving toward more convenient devices, dry-powder formats, and soft-mist approaches that may improve adherence and reduce tolerability issues such as cough.

•

Broader pulmonary fibrosis and interstitial lung disease markets are also seeing renewed innovation, including PDE4B inhibitors and other therapies aimed at slowing lung-function decline.

•

Rare disease pharmaceutical companies continue to benefit from high unmet need, specialist prescribing, and premium pricing, but they also face payer scrutiny and increasing evidence requirements.

•

Patent cliffs and portfolio transitions across the pharmaceutical industry can shift investor interest toward companies with durable growth and differentiated pipelines.

•

For United Therapeutics, these trends create a favorable environment for innovation but also raise the bar for clinical differentiation, launch execution, and lifecycle management.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on UTHR

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar

United Therapeutics authorized a $2 billion buyback

United Therapeutics authorized a $2 billion buyback

just authorized a share repurchase program of up to $2 billion, effective for one year through October 21, 2027. The company can potentially reduce its share count and increasing existing shareholders ownership percentage. However, do you think they'll be committed to spending the full amount?

avatar
@Simonwhite 7 months ago

United Therapeutics sees a massive jump after earnings

United Therapeutics sees a massive jump after earnings

it's pretty impressive to see United Therapeutics beat the earnings estimates by such a wide margin this quarter. i'm looking closely at to see if this momentum in their hypertension drugs can keep up despite the small revenue miss. what are your thoughts on their pipeline for the rest of the year?

avatar
@IsabelLynn 8 months ago

United Therapeutics earnings outlook

United Therapeutics earnings outlook

united therapeutics is showing a strong zacks rank lately, but that previous miss makes me a little nervous for the upcoming report. do you think can maintain its lead over the industry average or is the pulmonary franchise facing too much pressure right now?

avatar
@Simonwhite 8 months ago

united therapeutics shows real resilience

united therapeutics shows real resilience

it's pretty impressive to see United Therapeutics beat earnings estimates by that much despite a slight revenue miss. i've been watching for a bit and their focus on pulmonary hypertension treatments seems to be paying off. do you think this momentum will keep going through 2025?

No more topics to show